Results 21 to 30 of about 53,090 (292)
Development of specific nanobodies (VHH) for CD19 immuno-targeting of human B-lymphocytes [PDF]
Iranian Journal of Basic Medical Sciences, 2018 Objective(s): CD19 is a transmembrane glycoprotein of immunoglobulin superfamily. In order to treat lymphoma, monoclonal antibodies (mAb) can target different antigens, including CD19, CD20 and CD22 on the surface of B-cells.
Seyed Reza Banihahsemi +3 more
doaj +2 more sources
Minor population of NK lymphocytes with CD19 coexpression
Медицинская иммунологияSingle reports were published concerning a minor subpopulation of NK cells with weak coexpression of the B cell antigen CD19 in the patients’ blood and bone marrow.
A. A. Kalashnikova, N. V. Bychkova
doaj +2 more sources
A novel homozygous frameshift mutation likely causing nonsense-mediated mRNA decay in an Algerian kindred with CD19 complex deficiency [PDF]
Frontiers in ImmunologyBackgroundCD19 is an essential component of a membrane protein complex on B cells, which also includes complement receptor 2 (CD21), CD81, and CD225. It amplifies B cell receptor (BCR) signaling by recruiting regulatory molecules and facilitating the ...
Brahim Belaid +23 more
doaj +2 more sources
PD-1 checkpoint inhibition enhances the antilymphoma activity of CD19-CAR-iNKT cells that retain their ability to prevent alloreactivity [PDF]
Journal for ImmunoTherapy of CancerBackground Relapse and graft-versus-host disease (GVHD) are the main causes of death after allogeneic hematopoietic cell transplantation (HCT). Preclinical murine models and clinical data suggest that invariant natural killer T (iNKT) cells prevent acute
Anita Schmitt +17 more
doaj +3 more sources
Targeting the CD19/CD21 complex on B cells in the mixed lymphocyte reaction [PDF]
, 2022 B cells exert antigen presenting functions at the crossroad between immune activation and tolerance induction, a fate notably governed by the B Cell Receptor (BCR) response regulator CD19/CD21 complex. This duality in B cells raises a particular interest
Broc, Sabine
core +1 more source
Hematology, Transfusion and Cell Therapy, 2023 Introduction: The recent active use of immunotherapy based on CD19/CD3 bispecific T-cell engager (blinatumomab), brings significant problems on monitoring Minimal Residual Disease (MRD) based on Multiparameter Flow Cytometry (MFC), due to possible CD19 ...
RM Pontes +9 more
doaj +1 more source
Blood Advances, 2023 Abstract Therapy with CD19-directed chimeric antigen receptor (CAR) T cells has transformed the treatment of advanced B-cell malignancies. However, loss of or low antigen expression can enable tumor escape and limit the duration of responses achieved with CAR T-cell therapy. Engineering bispecific CAR T cells that target 2 tumor antigens
Isabel Leung +11 more
openaire +2 more sources
Cells, 2022 Given the importance of B lymphocytes in inflammation and immune defense against pathogens, mice transgenic for Cre under the control of Cd19 promoter (Cd19Cre/+ mice) have been widely used to specifically investigate the role of loxP-flanked genes in B ...
Ying Zhao +9 more
doaj +1 more source
Rejection of Experimental Hodgkins Lymphoma by T-cells Engineered with a CD19 Chimeric Antigen Receptor [PDF]
, 2012 T cells engineered to express chimeric receptors combining an external antibody binding domain with the CD3ζ T cell receptor (TCR) internal domain for triggering cell activation are being used for immunotherapeutic targeting of tumour cells in a non-HLA ...
Cheadle, Eleanor +8 more
core +1 more source
Antigen-specific cytokine profiles for pulmonary Mycobacterium avium complex disease stage diagnosis
Frontiers in Immunology, 2023 IntroductionControlling pulmonary Mycobacterium avium complex (MAC) disease is difficult because there is no way to know the clinical stage accurately. There have been few attempts to use cell-mediated immunity for diagnosing the stage.
Yoshiro Yamashita +16 more
doaj +1 more source